|
| Press Releases |
|
 |
|
| Thursday, June 12, 2025 |
|
|
耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段 |
| 在第62屆歐洲腎臟協會（ERA 2025）大會上，雲頂新耀（HKEX: 1952.HK）旗下全球首個對因治療IgA腎病藥物耐賦康®（布地奈德腸溶膠囊，NEFECON®）和新一代共價可逆BTK抑制劑EVER001都發佈了最新研究成果。 more info >> |
|
|
耐赋康(R)与EVER001协同发力 云顶新耀推动肾病治疗进入精准管理新阶段 |
| 在第62届欧洲肾脏协会（ERA 2025）大会上，云顶新耀（HKEX: 1952.HK）旗下全球首个对因治疗IgA肾病药物耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）和新一代共价可逆BTK抑制剂EVER001都发布了最新研究成果。 more info >> |
|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
|
雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑 |
| 在第62屆歐洲腎臟協會年會（ERA 2025）上，雲頂新耀（HKEX：1952.HK）自主研發、擁有全球權益的新一代共價可逆BTK抑制劑EVER001首次以集中口頭報告形式發佈其在原發性膜性腎病（pMN）中的階段性臨床研究數據。 more info >> |
|
|
云顶新耀EVER001亮相ERA 2025 探索原发性膜性肾病治疗新路径 |
| 在第62届欧洲肾脏协会年会（ERA 2025）上，云顶新耀（HKEX：1952.HK）自主研发、拥有全球权益的新一代共价可逆BTK抑制剂EVER001首次以集中口头报告形式发布其在原发性膜性肾病（pMN）中的阶段性临床研究数据。 more info >> |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
|
雲頂新耀宣佈耐賦康(R)獲得中國國家藥品監督管理局完全批准 全面拓展IgA腎病治療人群 |
| 今日，雲頂新耀（HKEX: 1952.HK）宣佈，其核心產品耐賦康(R)（布地奈德腸溶膠囊，NEFECON(R)）正式獲得中國國家藥品監督管理局（NMPA）完全批准。 more info >> |
|
|
云顶新耀宣布耐赋康(R)获得中国国家药品监督管理局完全批准 全面拓展IgA肾病治疗人群 |
| 今日，云顶新耀（HKEX: 1952.HK）宣布，其核心产品耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）正式获得中国国家药品监督管理局（NMPA）完全批准。 more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
|
雲頂新耀「摘B」成功 盈利能力與創新價值獲雙重驗證 |
| 今日，雲頂新耀（HKEX 1952.HK）宣佈公司已獲香港聯交所批准，將「B」標記從股票代碼中移除 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
アルゼンチンサッカー協会、Verofaxと提携しファン向けAI体験を提供
Jan 12, 2026 10:00: JST
|
|
|
Argentine Football Association (AFA) teams with Verofax to offer AI Experiences to Fans
Jan 12, 2026 08:00 HKT/SGT
|
|
|
Argentine Football Association (AFA) collabora con Verofax per offrire esperienze di IA ai tifosi
Jan 12, 2026 06:00 HKT/SGT
|
|
|
Metaspacex Limited Partners with Popcorn Technology to Expand into Web3.0 Digital Finance
Jan 11, 2026 20:59 HKT/SGT
|
|
|
中國數智科技與Popcorn Technology合作 進軍Web3.0數字金融領域
Jan 11, 2026 20:59 HKT/SGT
|
|
|
中国数智科技与Popcorn Technology合作 进军Web3.0数字金融领域
Jan 11, 2026 20:59 HKT/SGT
|
|
|
プロミセル社、JPモルガン2026年ヘルスケアカンファレンスで発表
Jan 10, 2026 20:00: JST
|
|
|
普瑞美細胞公司於摩根大通2026年醫療保健會議發表
Jan 10, 2026 19:00 HKT/SGT
|
|
|
普瑞美赛尔公司亮相摩根大通2026年医疗健康大会
Jan 10, 2026 19:00 HKT/SGT
|
|
|
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
Jan 10, 2026 07:00 HKT/SGT
|
|
|
賽力斯：以品牌和科技為基 開啟智慧豪華出行新紀元
Jan 9, 2026 16:07 HKT/SGT
|
|
|
赛力斯：以品牌和科技为基 开启智慧豪华出行新纪元
Jan 9, 2026 15:58 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 9, 2026 16:03 JST
|
|
|
市值超800億 成功上市的MiniMax以「極致效率」重塑全球AGI新格局
Jan 9, 2026 14:34 HKT/SGT
|
|
|
市值超800亿 成功上市的MiniMax以「极致效率」重塑全球AGI新格局
Jan 9, 2026 14:26 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
